Better Vision Optical Inc | |
Carr #2km 68.0 Bo Santana, Juarbe Center Local #3, Arecibo, PR 00612 | |
(787) 878-2460 | |
(787) 878-2460 |
Full Name | Better Vision Optical Inc |
---|---|
Type | Facility |
Speciality | Clinic/center |
Location | Carr #2km 68.0 Bo Santana, Arecibo, Puerto Rico |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1447382650 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | (* (Not Available)) | Primary |
261Q00000X | Clinic/center | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Better Vision Optical Inc Po Box 143154, Arecibo, PR 00614 Ph: (787) 878-2460 | Better Vision Optical Inc Carr #2km 68.0 Bo Santana, Juarbe Center Local #3, Arecibo, PR 00612 Ph: (787) 878-2460 |
News Archive
Combining some traditional experimental methods of molecular biology with computational methods of artificial intelligence, a group of researchers from Ruder Boskovic Instititute and Faculty of Natural Sciences and Mathematics from Zagreb, Croatia, demonstrated a novel approach for producing 'protein fingerprints' of diverse tissues.
Multiple, anatomically distinct lung cancer tumors may frequently arise from a single cancer cell, according to a retrospective analysis of patient tumor samples published in the April 7 online issue of the Journal of the National Cancer Institute.
Malaria is a life-threatening condition that exposes approximately half of the world's population to the risk of developing a severe and often lethal form of disease. In a study published in the latest issue of the journal Cell Host & Microbe*, Miguel Soares and his team at Instituto Gulbenkian de Ci-ncia (IGC), Portugal, discovered that the development of severe forms of malaria can be prevented by a simple mechanism that controls the accumulation of iron in tissues of the infected host.
ProteaBio Europe SAS, announced today that the company, in partnership with Mayoly-Spindler, has successfully completed a Phase I/IIA human clinical trial for their MS1819 recombinant Lipase.
› Verified 7 days ago